Week of March 14th 2022 | Vol. 11, Issue 11 |
|
|
In This Issue
Upcoming Events
Industry M&A Activity
Recent Transactions
Trading Comps
Market Reports
M&A Pipeline
Featured Headlines
Tanner Updates
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. Click on the chart to download complete transaction tables broken out by industry sub sectors. For additional information, see the Industry M&A Activity section below.
|
|
Events Hosted or Attended by Bourne Partners
|
|
|
|
March 16-18, 2022 - Aventura, FL
|
|
|
|
March 21-24, 2022 - New York City, NY
|
|
|
|
May 17-19, 2022 - Philadelphia, PA
|
|
|
|
May 24-26, 2022 - New York City, NY
|
|
|
|
April 23-26, 2022 - Palm Beach, FL
|
|
|
|
June 13-16, 2022 - San Diego, CA
|
|
|
|
August 27-29, 2022 - Boston, MA
|
|
|
|
October 2022 - Charlotte, NC
|
|
INDUSTRY M&A ACTIVITY
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
|
|
RECENT TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
|
|
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions. |
|
|
|
Pharma & Biotech
4 transactions totaling $14 million
Supplies, Equipment & Services
18 transactions totaling $404 million
Healthcare IT & Managed Care
6 transactions totaling $157 million
Healthcare Facilities & Distributors
6 transactions totaling $29 million
|
|
|
|
Pharma & Biotech
44 transactions totaling $1,088 million
Supplies, Equipment & Services
21 transactions totaling $135 million
Healthcare IT & Managed Care
20 transactions totaling $503 million
Healthcare Facilities & Distributors
3 transactions totaling $8 million
|
|
|
|
Pharma & Biotech
11 transactions totaling $1,495 million
Supplies, Equipment & Services
3 transactions totaling $280 million
Healthcare IT & Managed Care
2 transactions totaling $2 million
Healthcare Facilities & Distributors
1 transaction
|
|
TRADING COMPS
A Breakdown of Relevant Trading Multiples
|
|
|
|
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
MARKET REPORTS
Insight Into Healthcare Related Industries
|
|
M&A PIPELINE
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America
Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
|
|
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
|
|
FEATURED HEADLINES
A Sampling of Industry Headlines From Last Week
|
|
Creyon Bio wants to create drugs "on demand" for patient populations that consist of one person with a rare disease, or "millions" of people with common diseases—and a $40 million series A will help get that mission underway.
The new biotech is the latest to tout artificial intelligence and machine learning as the future of drug development, which inspired investors to buy in. Creyon wants to create oligonucleotide-based medicines using machine learning models that it claims are "orders-of-magnitude more efficient" than traditional trial-and-error screening, the startup said upon unveiling Tuesday. Oligonucleotides, or oligos, are short single strands of synthetic RNA or DNA.
Founders of the San Diego biotech are two Ionis Pharmaceuticals alums: President and CEO Chris Hart, Ph.D., and Chief Scientific Officer Swagatam Mukhopadhyay, Ph.D. Hart was previously executive director of functional genomics at Ionis until founding Creyon in October 2019, according to his LinkedIn bio. Mukhopadhyay jumped to Creyon in January 2020 after serving as principal computational biologist at Ionis.
|
|
March 8, 2022 - Fierce Pharma
|
Since May 2020, Eli Lilly’s had a plot picked out in North Carolina’s famed Research Triangle Park. The area's pull proved so fierce that Lilly last year snapped up 102 acres more. |
|
March 8, 2022 - Fierce Biotech
|
In Novartis’ perennial hunt for innovative therapies to bring under its wing, improving on gene therapy has always been kept top of mind. |
|
March 9, 2022- Fierce Biotech
|
Life science consulting firm Trinity Life Sciences is calling on the FDA to implement minimum representation requirements for clinical trials to help boost diversity in studies. |
|
March 3, 2022- Fierce Healthcare
|
International Women's Day was Tuesday, and, at the ViVE 2022 conference this week, the impact of female founders and executives touched almost every conversation about the future of healthcare and tech. |
|
The work of TannerGAP includes addressing medicine market withdrawal, post-clinical trial solutions, mitigating drug shortages and managing medicine supply on a Named Patient basis. Learn more from TannerGAP EVP, Maryori Alvarenga.
|
|
The Tanner team is continuously learning and seeking opportunities to enhance global access to new medicines and diagnostics. TannerLAC team members recently traveled to Germany to receive training on Epimune GmbH's i.Mune® tests, with future plans to bring the innovative product to Latin America. Learn more about the division’s first diagnostic product.
|
|
The Tanner team will be attending several networking events in the coming weeks. Let’s connect to discuss how our organizations can improve patient lives, together.
|
|
|
|
|
|
|
